The Fine Print Pays: A Covenant Checklist for UK Mid-Market Equity Investors

Equity investors in UK mid-market companies spend most of their diligence time on the business: the market, the management team, the unit economics, the exit route. The loan documentation is often delegated to advisers and read late. That ordering is a mistake. In a market where leverage multiples have compressed and lender processes have shortened, the covenant package is frequently the most informative document in the data room about how much room a company really has.

Leverage travels; covenants tell you where it lands

A stated multiple of four and a half times adjusted EBITDA is a price, not a risk measure. The number that matters is the multiple calculated under the facility agreement's own definition, tested on the lender's timetable, against a base case that may rest on add-backs the sponsor never sees in the management accounts. Two companies at the same headline leverage can sit at very different distances from a covenant breach, and the distance is the thing that determines whether the equity holder gets to make the next decision or watches it be made for them.

Mid-market sterling documentation still carries maintenance covenants in most transactions, unlike the covenant-lite structures that dominate larger syndicated loans. That is protective for lenders and constraining for owners, which makes understanding the detail more, not less, important.

Six checks before you underwrite

1. Maintenance or incurrence, and how tight?

Maintenance covenants are tested periodically, usually quarterly, against a net leverage and interest cover test in a compliance certificate. Incurrence covenants bite only on specific actions — taking on debt, paying dividends, making acquisitions. Establish which tests apply, at what levels, and with what equity cure rights attached. Then model the downside case: at what decline in EBITDA does the first test fail? If that figure sits uncomfortably close to a plausible trading scenario, the equity thesis needs to be stress-tested against it, not around it.

2. The EBITDA definition

The definitions schedule is the longest section of the agreement for good reason. Look for add-backs for restructuring costs, share-based payments, exceptional items and expected synergies. The important questions are whether synergy add-backs are capped, whether they must be realised within a defined period, and whether management retains discretion to classify costs as non-recurring. Uncapped run-rate adjustments can inflate covenant EBITDA well above the figure a buyer would pay for.

3. Baskets and carve-outs

General baskets, grower baskets and ratio-based capacity govern how much debt can be layered on, how many liens can be granted and how much cash can leave the business. For an equity investor, the leakage provisions matter most: permitted dividends, permitted payments to shareholders, and any available-amount mechanism that builds up with retained earnings. A generous basket is not necessarily a problem, but it is a claim on future cashflow that sits ahead of reinvestment.

4. Security and guarantee coverage

A UK debenture creating fixed and floating charges over domestic assets is standard. The questions are coverage thresholds, material subsidiary definitions and whether overseas operations are inside the guarantee perimeter. If a meaningful share of group EBITDA sits in jurisdictions outside the security net, recovery in a downside scenario is weaker than the leverage multiple implies. Check the intercreditor arrangements too, particularly in unitranche and super-senior structures where the ranking and the voting rights are not symmetrical.

5. Equity cure rights

Cure rights allow an owner to inject cash to remedy a breach, usually treated as EBITDA for testing purposes. They are a useful tool and a common feature of mid-market deals. But a cure disguises deterioration as effectively as it fixes it, and repeated cures can dilute co-investors or shift the economics of the equity story. Read the caps on the number of cures, the amounts, and whether the lender must accept them.

6. Permitted acquisitions and capex

Acquisition baskets and capital expenditure allowances set the boundary between disciplined investment and overreach. A company permitted to spend heavily on bolt-ons without lender consent can transform its risk profile between reporting dates. Conversely, restrictive capex covenants can force under-investment in a business that needs to modernise, which is a slower but equally real erosion of value.

Where equity value erodes first

Value rarely disappears in a single quarter. It leaks through smaller, visible markers. Covenant headroom narrows from forty per cent to twenty to ten. The add-backs grow each year as the underlying earnings quality softens. A covenant reset is agreed, described as a technical amendment. An incremental facility is raised under a basket that no one modelled. A waiver is obtained and the reporting pack grows thinner.

Each of these is a data point, and together they describe a trajectory. An investor who receives only summary management accounts will miss all of it. An investor who asks for the compliance certificate history will see it clearly.

Diligence in practice

Four requests should be routine. The last three years of compliance certificates and covenant calculations. Any waivers, amendments or forbearance correspondence with lenders. The intercreditor deed and the security documents, not just the summary. And, where possible, a direct conversation with the lender or agent, who will often say in ten minutes what the documentation takes an hour to imply.

Independent covenant review is inexpensive relative to the size of a mid-market equity cheque and considerably cheaper than discovering a restriction after the business has begun to underperform. The documentation is the immune system of the capital structure: it decides how the company responds to stress. Equity holders who never read it are relying on someone else's judgement about where their downside begins.